睿诺医疗科技

Ruinuo Medical Technology (Shanghai) Co., Ltd., also known as Farsight Pharma, is a clinical-stage biotechnology company specializing in the development of innovative cyclophilin inhibitors. Founded in 2016 and headquartered in Shanghai's Zhangjiang High-Tech Park, the company leverages its proprietary technology platform to target Cyclophilin A (CypA) and Cyclophilin D (CypD) for the treatment of inflammatory, viral, and neurodegenerative diseases. Its lead candidate, RN-0001, is a first-in-class small molecule inhibitor currently in Phase 2 clinical trials for acute pancreatitis and acute kidney injury. The company's pipeline also includes programs for hepatitis B and D, as well as various neurodegenerative conditions, aiming to address significant unmet medical needs through novel mechanisms of mitochondrial and inflammatory regulation.